preprint · F1000Research
<ns3:p>Since its occurrence, the coronavirus disease 2019 (COVID-19) pandemic has been responsible for a substantial rate of morbidity and mortality. The quick development of an effective and safe vaccine was essential in order to control the ongoing pandemic. However, given the severity of the situation, mass-scale vaccination had to be undertaken without much hindsight. Subsequently, side effects of the anti-COVID-19 vaccine, such as autoimmune diseases, have been reported. Cryoglobulinemic vasculitis (CryoVas) is a rare auto-immune disease, caused by the presence in the serum of abnormal immunoglobulins (cryoglobulins) able to precipitate at temperatures below 37°C. CryoVas can be either essential or, more frequently, secondary to other diseases such as infections, malignancies and auto-immune diseases. In some cases, CryoVas can be vaccine-induced. We describe an original case of a 57-year-old woman with no medical history who presented with purpura of the lower limbs that appeared 5 days after receiving her first COVID-19 vaccine. Skin biopsy and immunological work out were consistent with CryoVas.</ns3:p>
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.12688/f1000research.142144.1
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
